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Resta (2009) in his Commentary clearly articulates how
another breast cancer gene discovery would significantly
impact the genetic counselors’ workload and appropriately
urges us to think about these issues and be proactive. But a
hypothetical BRCA3 gene is just the tip of the iceberg. The
tsunami is genomic medicine, testing for common, complex
conditions and personalized medicine. Are we ready to
respond to patients’ requests to order these tests, evaluate
data or interpret reports from whole genome scans?
For the hypothetical BRCA3 gene, Resta (2009) pro-
poses that we proactively develop protocols for re-
contacting patients that can be implemented with short
notice, set up clinic databases with pedigrees and genetic
test results to efficiently identify patients who need to be re-
contacted and then create mail merge letters. I think time-
wise and logistically, this is not practical. As Resta (2009)
has already pointed out in his Commentary, we are doing
all that we can to keep up with our current caseloads. Re-
contacting past patients would simply be relegated to the
bottom of the perpetual “to do” list of tasks for patients,
behind the insurance letters that have to be written to justify
needed genetic testing. Given technology capabilities and
electronic medical records, just like mammogram reminders
are increasingly being used, this could similarly be imple-
mented for a number of medical and genetic conditions.
However, while re-contacting patients would be globally
beneficial in healthcare, the fact is that we currently do not
put this responsibility on other physicians and there are both
significant time and logistical issues.
But there are alternatives. First, put the onus on the
patient to re-contact the clinic to inquire whether there have
been any updates in genetic testing and treatment since their
appointment and include this instruction in visit documen-
tation. Second, encourage patients to join, visit the websites
or call genetic support groups since these groups will often
have up-to-date information about advances in care and
genetic testing. Third, time to re-contact patients could
instead be used to create and update clinic websites with
pertinent information.
Patients could access the clinic website pre and post their
appointments for information including basic genetic
concepts, patterns of inheritance, genetic conditions (e.g.
Genetics Home Reference), genetic testing and factors to
consider, insurance issues and links to support group
directories. I propose that GeneTests develop a page that
clinics could link to that would list genetic conditions,
indicate if genetic testing is available and last date there
was a significant change in testing. The clinic website
would include a standard disclaimer about use of web
information and the need to make medical decisions in
consultation with a physician along with a statement
emphasizing that a genetic test does not take the place of
a genetic evaluation and that there are several factors to
consider. Patients previously seen could easily use the clinic
website to look up the genetic condition, determine if
genetic testing has changed since their visit and initiate
contact with the clinic. For patients with no computer, a call
to the clinic or use of public library computers would be
encouraged. The fact is, patients are using the Internet to
obtain genetic testing information and some are even
having direct-to-consumer genetic testing.
Resta (2009) states that “...whatever testing is done will
likely entail a DNA sample and plenty of explanation.”
Many tests are done in our healthcare without “plenty of
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explanation.” As Resta (2009) points out, “Many patients
will only vaguely remember the initial counseling details”; I
agree. In order to enhance understanding and avoid
information overload, we need to rethink the information
that needs to be conveyed so that risks are understood and
informed decisions can be made about genetic testing and
healthcare. Is a genetics mini-lesson on chromosomes,
genes etc. a necessary part of a clinic visit? Could we
provide patients with an information sheet before or during
the clinic visit or is such an explanation even needed?
Patients often want to know their bottom-line risk and are
less interested in how the risk figure was derived. When
newborn screening is done, there is not a detailed
explanation of the incidence and pattern of inheritance of
each condition. It is sufficient to know that these conditions
have increased morbidity and mortality and for some
conditions, early treatment is of benefit. We need to work
on determining when genetic testing merits more discussion
(e.g. predictive genetic testing; genetic tests with low
sensitivity; tests with complex interpretations etc.) versus
when it can be done like newborn screening or a CBC.
There will be an increasing number of genetic tests for
common complex conditions and in tests that will just be
risk modifying. I agree with Resta (2009) that genetic tests
should be rigorously evaluated before introduction into
clinical practice and to discuss DNA banking with patients.
We should also encourage specialists and primary care
physicians to discuss this option in cases where lifespan is
limited.
Genetic clinic visits have typically focused on a single
indication. With the era of genomic medicine, the focus will
shift from uncommon Mendelian inherited conditions to
addressing a number of genetic conditions during a clinic
visit. We need to rethink the time involved and what can be
accomplished in clinic visits (traditional visits are often an
hour or more), and recognize that more than one clinic visit
will be necessary to address all genetic issues, just like
standard medical care. To keep the counseling in genetic
counseling, we need to have time to raise and address
psychosocial issues and not defer this as a discussion only
if time permits. Resta (2009) states that “Complicated
psychological and emotional issues will often emerge.”
While such issues can be complicated, there are a number
of patients who just want the information or “the test” with
no psychosocial exploration. However, it is important that
we give patients the opportunity to have psychosocial
issues discussed, and provide helpful resources.
We need to globally think about developing other
genetic service delivery models, including having patients
enter family history information by computer at home or in
the waiting room with electronic pedigree generation, group
education sessions (and use of CD-ROMS, videos, com-
puter programs) followed by individual genetic counseling
for commonly seen conditions and other changes. With all
models (and points in this Commentary), we need to
consider options for underserved populations, patients with
learning disabilities, physical disabilities and language
barriers.
With the era of genomic and personalized medicine,
everyone in the population is potentially a patient.
Therefore, there will be a “flood” of patients who will
need genetic issues addressed and genetic testing but not all
of these patients need to be seen in genetics clinics. Resta
(2009) states that if patients cannot be seen in a timely
manner in genetics clinics, “this increases the likelihood
that patients will be inadequately counseled by non-genetic
specialists and that test results will be inaccurately
interpreted.” This statement is simply not true and incorrect-
ly implies that only geneticists can accurately interpret
genetic test results. Genetic counselors and geneticists do
need to be proactive in developing triaging guidelines and
genetic testing algorithms and seek input from specialists
and primary care physicians. Which are the patients who
should be seen in the genetics clinic versus by a specialist
or by a primary care physician? What resources and
guidelines can we provide primary care physicians so that
they will know when referral is indicated and when genetic
testing should be ordered versus deferred to a specialist or
genetics clinic? This has been successfully done with
maternal serum screening during pregnancy where testing
is ordered by obstetricians and patients with abnormal
values are often referred to prenatal genetics clinics. We are
experts in genetics and clinical care applications and need
to continue to share our expertise, including publishing
articles in the medical literature, developing resources for
physicians and patients, giving presentations and serving
on committees.
As we transition from Mendelian conditions to genomic
medicine, common complex diseases and personalized
medicine, we need to:
1) Keep educating each other through online courses,
presentations at our Annual Education Conferences and
regional meetings, journal publications and resources at
our website.
2) Think globally about models of providing genetic
services and recognize that additional models need to
be developed. We need to focus on key components of
genetic counseling including risk assessment and
communication, education about the genetic condition,
facilitation of decision-making, addressing psychoso-
cial issues and providing supportive resources.
3) Change our standards for how we document traditional
genetics clinic visits. Letters can sometimes take as
long to compose as the clinic visit itself. Rather than
generate 3+ page summaries of clinic visits that explain
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chromosomes, genes, patterns of inheritance, risk
figures and their derivations, instead give bottom-line
summary statements and cite information sheets and
the clinic website for further explanation of basic
genetic concepts. Many clinics do use template letters
however these letters are often still long.
4) Collaboratively develop triaging guidelines and testing
algorithms. Develop guidelines and points to consider
for types of genetic tests (e.g. diagnostic, carrier,
predictive) since development of this information for
each genetic test will take years. NSGC’s Special
Interest Groups (SIGs) can initiate developing guide-
lines for genetic conditions in their specialty area.
5) Continue to educate insurers about the value of genetic
testing, implications for family members and potential
savings to our healthcare system. For genetic condi-
tions that require screening with echocardiograms,
MRIs or CT scans, the cost of any of these tests, done
even once, will far exceed the cost of most genetic
tests. Healthcare dollars can be saved if patients, who
are not at increased risk by genetic testing, no longer
undergo costly screening.
6) Teach patients to be educated seekers of information.
Put the onus on patients to contact genetic support
groups/visit websites and re-contact the genetics clinic
to learn about advances in treatment and genetic testing
for their genetic condition.
I agree with Resta (2009) that “professional, patient,
industry and government organizations must work together.”
In order to provide the best care, we need to reassess the
services to provide, what information needs to be communi-
cated, what is best for us to do and what can be done by other
healthcare professionals and even by patients themselves. The
genomic train has already left the station and we need to do
what we can to keep it on the right track.
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